Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-05
DOI
10.1038/s41408-018-0154-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
- (2018) Sara Bringhen et al. LEUKEMIA
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
- (2016) James R. Berenson et al. BLOOD
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Myeloma today: Disease definitions and treatment advances
- (2015) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
- (2015) Salma Afifi et al. PHARMACOTHERAPY
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
- (2014) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- (2012) Jeffrey L. Wolf et al. LEUKEMIA & LYMPHOMA
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
- (2010) C R Giver et al. LEUKEMIA
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started